-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olokizumab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olokizumab in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olokizumab in Rheumatoid Arthritis Drug Details: Olokizumab (Artlegia) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Small-Cell Lung Cancer Drug Details: NLG-207 (CRLX-101) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapirolizumab Pegol in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapirolizumab Pegol in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapirolizumab Pegol in Systemic Lupus Erythematosus Drug Details: Dapirolizumab pegol...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cetuximab Biosimilar in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cetuximab Biosimilar in Ovarian Cancer Drug Details: Cetuximab biosimilar (CDP-1) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olokizumab in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olokizumab in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Olokizumab in Rheumatoid Arthritis Drug Details: Olokizumab (Artlegia) is a humanized monoclonal antibody....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Epithelial Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Epithelial Ovarian Cancer Drug Details: NLG-207 (CRLX-101) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Romosozumab in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romosozumab in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Romosozumab in OsteoporosisDrug Details: Romosozumab (Evenity) is a humanized monoclonal antibody. It is formulated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Romosozumab in Osteogenesis Imperfecta
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romosozumab in Osteogenesis Imperfecta report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Romosozumab in Osteogenesis Imperfecta Drug Details: Romosozumab (Evenity) is a humanized...
-
Company Profile
Sitecore Corp AS – Company Profile
Sitecore Corp AS (Sitecore), a subsidiary of Sitecore Holding II AS, is a provider of management software and web context marketing platform solutions. The company offers content cloud, engagement cloud and commerce cloud platform products. Its major offerings include Content Hub One, XM Cloud, Digital Experience Platform (DXP), Sitecore CDP and OrderCloud. Sitecore’s solution portfolio comprises personalization and testing, marketing automation, order management, customer data management, content management, search and merchandising, digital asset management, content operations, storefront and marketplaces. It...
Add to Basket